Ticovac Global Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

TicoVac is a vaccine designed to protect against tick-borne encephalitis (TBE), a viral infection primarily transmitted through tick bites or, less commonly, by consuming unpasteurized dairy products from infected animals. TBE affects the central nervous system and can result in serious neurological complications, including meningitis and encephalitis. TicoVac works by activating the immune system to recognize and combat the tick-borne encephalitis virus (TBEV) upon future exposure.

The main formulations of TicoVac are inactivated vaccines and live attenuated vaccines. Tick-borne encephalitis is a viral disease spread through infected tick bites, affecting the central nervous system and potentially causing severe neurological issues. The vaccine is used for tick-borne encephalitis, Japanese encephalitis, and rabies encephalitis, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

Tariffs have influenced the ticovac market by increasing costs associated with imported vaccine ingredients, sterile packaging materials, and temperature controlled logistics systems. These tariff pressures have affected hospital pharmacies and government vaccination programs that rely on cross-border supply chains. Regions such as europe face moderate cost escalation due to dependence on imported vaccines. At the same time, tariffs are encouraging regional vaccine manufacturing investments. This is supporting long-term supply resilience and distribution stability.

The ticovac market research report is one of a series of new reports from The Business Research Company that provides ticovac market statistics, including ticovac industry global market size, regional shares, competitors with a ticovac market share, detailed ticovac market segments, market trends and opportunities, and any further data you may need to thrive in the ticovac industry. This ticovac market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ticovac market size has grown strongly in recent years. It will grow from $4.31 million in 2025 to $4.63 million in 2026 at a compound annual growth rate (CAGR) of 7.5%. The growth in the historic period can be attributed to endemic presence of tick-borne encephalitis, public health vaccination initiatives, growing outdoor activity exposure, hospital based immunization programs, regulatory approvals for tbe vaccines.

The ticovac market size is expected to see strong growth in the next few years. It will grow to $6.11 million in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to expansion of vaccination coverage in europe, rising travel to endemic regions, increasing climate driven tick populations, stronger preventive healthcare policies, investment in vaccine infrastructure. Major trends in the forecast period include rising demand for tick-borne disease vaccination, expansion of preventive travel immunization, growth of government led vaccination programs, increased awareness of vector-borne diseases, improved cold chain vaccine distribution.

The rising prevalence of tick-borne diseases is expected to drive the growth of the Ticovac market in the coming years. Tick-borne diseases are infections transmitted to humans through the bites of infected ticks, caused by bacteria, viruses, or parasites. Their increasing incidence is linked to factors such as climate change, expanding tick habitats, greater human exposure, and improved diagnostic methods. Ticovac plays a critical role in prevention by providing active immunization against tick-borne encephalitis (TBE), a potentially severe viral infection transmitted through tick bites. For example, in February 2024, the Centers for Disease Control and Prevention reported that the overall incidence of Lyme disease in the U.S. was 18.9 cases per 100,000 population, representing a 68.8% increase compared to previous years. Among high-incidence regions, the median rate rose 58% to 68.3 cases per 100,000, while for children aged 5-9 years, the incidence reached 16.5 cases per 100,000, reflecting an 11.5% increase. Consequently, the rising prevalence of tick-borne diseases is driving the Ticovac market.

The increasing focus on research and development (R&D) activities is also expected to support the growth of the Ticovac market. R&D involves systematic scientific investigation to create new products, improve existing ones, and develop innovative technologies. Rising R&D efforts are driven by growing demand for innovation, technological progress, and the need to address emerging global health challenges. These activities positively impact Ticovac by advancing vaccine formulations, enhancing efficacy, and ensuring its continued effectiveness against emerging strains of tick-borne encephalitis. For example, in February 2025, the National Center for Science and Engineering Statistics reported that U.S. research and development expenditures increased from $892 billion in 2022 to $940 billion in 2023, a rise of $48 billion. Therefore, the growing research and development efforts are driving the Ticovac market.

Key companies in the Ticovac market are focusing on innovative formulations, such as suspension liquid vaccines, to gain a competitive advantage. Suspension liquid vaccines are designed for intramuscular injection and are available in 0.5 mL doses suitable for both adults and pediatric patients. For instance, in September 2024, Pfizer Inc., a U.S.-based pharmaceutical company, launched Ticovac in Japan as the first vaccine aimed at preventing tick-borne encephalitis (TBE) in the region. The vaccine is offered in two versions-one for adults and one for children-both administered as 0.5 mL intramuscular injections, providing protection in areas where TBE is prevalent.

Major companies operating in the ticovac market are Pfizer Inc.

Europe was the largest region in the ticovac market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the ticovac market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ticovac market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

The ticovac market consists of sales of pediatric vaccines, cardiovascular and metabolic products, anti-infective medications and rare disease medications. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ticovac Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ticovac market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ticovac ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ticovac market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Formulation: Inactivated Vaccines; Live Attenuated Vaccines
• 2) By Indication: Tick-Borne Encephalitis; Japanese Encephalitis; Rabies Encephalitis
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Companies Mentioned: Pfizer Inc.
• Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.